The Executive Officers of Zai Lab Limited , Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, announced that they have each agreed that they do not anticipate selling any shares in Zai Lab through the remainder of 2024, except for any shares in existing Rule 10b5-1 plans that are currently effective or to cover tax obligations associated with the vesting of equity awards
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Zai Lab, Bristol Myers: Krazati confirmatory trial meets PFS primary endpoints
- Zai Lab says partner Novocure’s Phase 3 trial met primary endpoint
- Zai Lab price target lowered to $66 from $123 at Citi
- Zai Lab Ltd’s New Share Price & Shareholder Rights Risk – A Cause for Worry?
- Zai Lab reports FY23 EPS (35c), consensus ($3.15)
